FORGE Life Science Founders, Ileana Cristea, Emre Koyuncu, and Thomas Shenk publish their breakthrough discovery that “Sirtuins Are Evolutionarily Conserved Viral Restriction Factors”. Read more
FORGE Life Science receives JumpStart Award announced at PA BIO Life Sciences Futures annual meeting in Philadelphia, PA. Read more
FORGE Life Science featured in the Innovator’s Corner of PharmaVoice magazine. Read more
Dr. Stacy Remiszewski, former Director of Chemistry, Section Head for Oncology Chemistry at Hoffmann-La Roche, joins FORGE Life Science as Head Of Chemistry.
FORGE Life Science LLC is awarded a second grant from the NIH National Institute for Allergy and Infectious Disease titled, “A Single Antiviral to Treat Multiple Opportunistic Infections” (1R43AI114079-01). Read more
FORGE Life Science LLC grant titled, “Host-Targeted Mechanism of Action for Treatment of Seasonal and Pandemic Influenza”, is awarded by the NIH National Institute for Allergy and Infectious Diseases (1R43AI110048-01). Read more
FORGE Life Science LLC exclusively licenses Sirtuin-Antiviral Technology from Princeton University.
FORGE Life Science LLC leases BSL2+ facilities from the Pennsylvania Biotechnology Center.